The American Society of Gene and Cell Therapy conference is buzzing with discussions about Baby KJ and the absence of Vinay Prasad. Last year, Peter Marks, the FDA’s head of biologics, was a prominent figure at the conference, viewed as an ally in the approval of rare disease treatments. However, Marks has been replaced by Vinay Prasad, a vocal hematologist known for his critical stance towards pharmaceutical companies.
Many in the gene therapy field are curious about Prasad’s approach to rare disease treatments, especially considering his history of challenging the evidence behind certain medical interventions. The departure of Marks and the arrival of Prasad have raised questions about the future direction of gene therapy regulation and approval processes.
Unfortunately, access to the full article discussing Prasad’s potential impact on the gene therapy field is restricted to STAT+ subscribers. To unlock this exclusive content and gain access to in-depth analysis, newsletters, premium events, and news alerts, interested readers can subscribe to STAT+.
In the rapidly evolving landscape of gene and cell therapy, the regulatory decisions made by figures like Vinay Prasad can have a significant impact on the development and availability of life-saving treatments. Stay tuned for more updates on the latest developments in gene therapy research and regulation.
